US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Fidelity Disruptive Medicine ETF

31.30

-0.1066-0.34%

Post-market: 31.26-0.0434-0.14%19:30 EDT

Volume:2K

Turnover:77.92K

Market Cap:50.83M

PE:- -

High:31.42

Open:31.22

Low:31.20

Close:31.41

52wk High:32.89

52wk Low:23.48

Shares:1.62M

Float Shares:1.62M

Volume Ratio:0.34

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Thermo Fisher Eyes 15%-20% India Customer Growth on Biopharma Research, Manufacturing Boost

10x Genomics (TXG) Stock Rally Leans On Margin Gains And Cash

Simply Wall St.

Thermo Fisher CEO Marc Casper Disposes of USD 8.01 Million in Common Shares

Steris PLC Stock Outperforms Competitors on Strong Trading Day

10x Genomics is Maintained at Equal-Weight by Morgan Stanley

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and 10x Genomics (TXG)

Analysts Are Bullish on These Healthcare Stocks: Becton Dickinson (BDX), 10x Genomics (TXG)

Morgan Stanley Adjusts PT on Lifestance Health Group to $13 From $10, Maintains Overweight Rating

MT Newswires Live

10x Genomics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

10x Genomics Q2 Revenue Rises on Atera Demand

10x Genomics Q2 Swings to Loss, Revenue Falls

MT Newswires Live

Canada's WELL Health Q2 Revenue Rises, Lifts 2026 Outlook

10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate

Benzinga Earnings

10X Genomics Q2 Revenue USD 151 Million Vs. IBES Estimate USD 146.8 Million

LifeStance Raises Fy2026 Revenue Outlook to $1.685 Billion-$1.725 Billion

LifeStance Health Group, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Lifestance Health Swings to Q2 Profit as Revenue Rises; Raises 2026 Revenue Guidance

MT Newswires Live

Lifestance Health Lifts Outlook After Strong Q2 Results

LifeStance Q2 FY26 Net Income Turns to USD 23.6 Million; Revenue Rises 26% to USD 435.4 Million

Lifestance Health Q2 Revenue USD 435.4 Million Vs. IBES Estimate USD 414.6 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/FMED/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FMED\",,,,,undefined,":{"symbol":"FMED","market":"US","secType":"STK","nameCN":"Fidelity Disruptive Medicine ETF","latestPrice":31.3034,"timestamp":1789502400000,"preClose":31.41,"halted":0,"volume":2488,"hourTrading":{"tag":"盘后","latestPrice":31.26,"preClose":31.3034,"latestTime":"19:30 EDT","volume":7,"amount":219.1238,"timestamp":1789515005451,"change":-0.0434,"changeRate":-0.001386,"amplitude":0},"delay":0,"changeRate":-0.003393823623049992,"floatShares":1623806,"shares":1623806,"eps":0,"marketStatus":"Not Yet Opened","change":-0.1066,"latestTime":"09-15 16:00:00 EDT","open":31.22,"high":31.42,"low":31.2001,"amount":77919.318352,"amplitude":0.007001,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":31.41,"sharesOutstanding":2323806,"nav":30.831238,"aum":50953312.669446,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.26,"preClose":31.3034,"latestTime":"19:30 EDT","volume":7,"amount":219.1238,"timestamp":1789515005451,"change":-0.0434,"changeRate":-0.001386,"amplitude":0},"volumeRatio":0.344799,"impliedVol":0.0711,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FMED\",,,,,undefined,":{"symbol":"FMED","floatShares":1623806,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.344799,"shares":1623806,"dividePrice":0,"high":31.42,"amplitude":0.007001,"preClose":31.41,"low":31.2001,"week52Low":23.48,"pbRate":"--","week52High":32.8877,"institutionHeld":0,"latestPrice":31.3034,"eps":0,"divideRate":0,"volume":2488,"delay":0,"ttmEps":0,"open":31.22,"prevYearClose":27.05,"prevWeekClose":31,"prevMonthClose":31.775,"prevQuarterClose":28.525,"fiveDayClose":31.542,"twentyDayClose":30.5871,"sixtyDayClose":26.1028},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FMED\",params:#limit:5,,,undefined,":[{"date":"2024-12-20","symbol":"FMED","amount":0.112,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Fidelity Disruptive Medicine ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-24"},{"date":"2024-06-21","symbol":"FMED","amount":0.001,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-21","defaultRemindTime":1718976600000,"name":"Fidelity Disruptive Medicine ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-25","payableDate":"2024-06-21","currency":"USD","dateTimestamp":1718942400000,"payDate":"2024-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FMED\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-21","recordDate":"2024-06-21","paymentDate":"2024-06-25","value":0.001,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-24","value":0.112,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FMED\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658989038","title":"Thermo Fisher Eyes 15%-20% India Customer Growth on Biopharma Research, Manufacturing Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2658989038","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658989038?lang=en_us&edition=fundamental","pubTime":"2026-08-10 16:44","pubTimestamp":1786351490,"startTime":"0","endTime":"0","summary":"UPDATE 1-Thermo Fisher eyes 15%-20% India customer growth on biopharma research, manufacturing boostHYDERABAD, Aug 10 (Reuters)-Thermo Fisher ScientificTMO.Nis eyeing a 15%-20% increase in its custome","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4N4470EJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","GNMX","LU2125909759.SGD","LU1153585028.USD","IE00BKPKM429.USD","LU2125910336.SGD","IE00BQXX3C00.GBP","BK4585","LU1064131342.USD","FMED","LU1291159041.SGD","LU2764263203.CNY","LU0011850046.USD","LU1815333072.USD","TMO","LU0122379950.USD","LU1280957306.USD","LU2764262908.HKD","IE00B19Z8X17.USD","IE0002141913.USD","IE00BQXX3D17.EUR","LU1712237335.SGD","LU0320765489.SGD","LU2125910179.SGD","BK4534","LU1803068623.USD","LU1720051108.HKD","LU1989771016.USD","LU0957791311.USD","IE00BFTCPJ56.SGD","TMED","BK4121","LU0096362180.USD","BK4588","LU0640476718.USD","LU1988902786.USD","LU0345770308.USD","LU0208291251.USD","LU0823416689.USD","IE00BJJMRZ35.SGD","HRTS","LU2543165471.USD","LU2125909247.SGD","IE00B19Z8W00.USD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4566","LU0528227936.USD","IE00B2B36J28.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657419624","title":"10x Genomics (TXG) Stock Rally Leans On Margin Gains And Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2657419624","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657419624?lang=en_us&edition=fundamental","pubTime":"2026-08-08 07:46","pubTimestamp":1786146379,"startTime":"0","endTime":"0","summary":"10x Genomics stock jumped 14.1% to about US$52 after its Q2 report, and the move appears to reflect sentiment rather than a sudden profit breakthrough. The company still reported a loss per share and quarterly revenue of US$151 million, so the market is effectively reacting to the quality of the loss, not the absence of it.\nThe key focus for traders is margin and balance sheet resilience. Gross margin improved to roughly 74%, and cash and marketable securities stood at US$552 million. Today’s...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-stock-rally-leans-on-margin-gains-and-cash","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-stock-rally-leans-on-margin-gains-and-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4548","BK4585","LU1861558580.USD","LU1861559042.SGD","FMED","BK4121","TXG","BK4588","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657725629","title":"Thermo Fisher CEO Marc Casper Disposes of USD 8.01 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657725629","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657725629?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:26","pubTimestamp":1786138000,"startTime":"0","endTime":"0","summary":"Thermo Fisher CEO Marc Casper disposes of USD 8.01 million in common sharesThermo Fisher Chairman and CEO Marc N. Casper exercised stock options for 10,000 shares at USD 309.63 on Aug. 5, 2026.Casper ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDLbStzZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Thermo Fisher CEO Marc Casper Disposes of USD 8.01 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMO","IE00BFTCPJ56.SGD","LU2764262908.HKD","LU1633808545.USD","LU0823416689.USD","LU2764263203.CNY","IE00B19Z8W00.USD","LU0316494557.USD","BK4548","BK4535","LU1791710582.SGD","LU2720916845.USD","IE00B19Z8X17.USD","IE00BQXX3D17.EUR","FMED","LU0640476718.USD","LU2089984988.USD","LU0114720955.EUR","LU1548497426.USD","GB00BDT5M118.USD","HRTS","IE00BQXX3F31.USD","LU2211815571.USD","TMED","LU1280957306.USD","LU1023059063.AUD","LU1670628061.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU2543165471.USD","LU0320765489.SGD","LU1720051017.SGD","LU1061106388.HKD","LU0882574055.USD","LU0345770308.USD","LU2211814178.USD","LU2112291526.USD","GNMX","LU1057294990.SGD","IE0009355771.USD","LU2063271972.USD","IE00BJJMRZ35.SGD","LU0234572021.USD","LU0345770993.USD","BK4121","IE00B4R5TH58.HKD","LU1854104046.USD","BK4581","LU0011850046.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657291556","title":"Steris PLC Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2657291556","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657291556?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:05","pubTimestamp":1786136700,"startTime":"0","endTime":"0","summary":"DJ Steris PLC Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Steris PLC  rallied 2.45% to $237.47 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.62% to 7,757.64 and the Dow Jones Industrial Average  rising 0.28% to 54,036.93.The stock's rise snapped a two-day losing streak.Steris PLC closed 11.87% short of its 52-week high of $269.44, which the company achieved on January 16th.The stock outperformed some of its competitors Friday, as Thermo Fisher Scientific Inc.  rose 2.41% to $594.00, Danaher Corp.  rose 2.39% to $204.76, and Becton Dickinson & Co.  fell 0.12% to $176.86.Trading volume  remained 18,525 below its 50-day average volume of 820,294.Data source: Dow Jones Market Data, FactSet. Data compiled August 7, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995401.HKD","HRTS","SG9999013999.USD","BDX","LU0289739343.SGD","LU2112291526.USD","LU2720916845.USD","LU0011850046.USD","LU1989771016.USD","IHI","BK4548","LU0878866978.SGD","LU1059921491.USD","LU0342679015.USD","LU0109391861.USD","LU1150488135.SGD","LU0689472784.USD","LU1571399168.USD","LU0162691827.USD","LU0345770993.USD","LU2360108059.USD","LU0320765489.SGD","SG9999001176.SGD","BK4588","SGXZ57979304.SGD","LU2244417387.USD","LU0068578508.USD","LU1670628061.USD","LU0672654240.SGD","IE00BZ1G4Q59.USD","TMED","LU0820561818.USD","LU1720051108.HKD","LU0985489474.SGD","LU0820562030.AUD","DHR","TMO","FMED","GB00BDT5M118.USD","STE","IE00BQXX3C00.GBP","LU2355687059.USD","LU0130518102.USD","LU0312595415.SGD","LU0107464264.USD","LU2265009873.SGD","LU2125909759.SGD","LU0320765059.SGD","GNMX","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657862380","title":"10x Genomics is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657862380","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657862380?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:27","pubTimestamp":1786127220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TXG/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4585","TXG","ARKG","FMED","BK4588","LU1861558580.USD","LU1861559042.SGD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657362873","title":"Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and 10x Genomics (TXG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657362873","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657362873?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:00","pubTimestamp":1786125646,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verrica Pharmaceuticals (VRCA) and 10x Genomics (TXG). Verrica Ph...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-10x-genomics-txg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-10x-genomics-txg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","LU1861559042.SGD","BK4121","BK4585","ARKG","BK4137","LABU","FMED","VRCA","TXG","BK4588","XBI","BK4007","HCSG","XLV","BK4548","LU1861558580.USD","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657646498","title":"Analysts Are Bullish on These Healthcare Stocks: Becton Dickinson (BDX), 10x Genomics (TXG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646498","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657646498?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:00","pubTimestamp":1786107618,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Becton Dickinson (BDX), 10x Genomics (TXG) and Steri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-becton-dickinson-bdx-10x-genomics-txg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-becton-dickinson-bdx-10x-genomics-txg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0985489474.SGD","LU0433182093.SGD","FMED","LU0511384066.AUD","LU1150488135.SGD","LU0477156797.USD","LU1894683264.USD","LU1854103824.USD","LU1489326972.SGD","LU0648000940.SGD","ARKG","LU0130518102.USD","LU0266013472.USD","LU0006061336.USD","IHI","LU0162691827.USD","TXG","BK4504","LU0068578508.USD","BK4588","LU1201861165.SGD","LU1861558580.USD","BK4585","LU0130103400.USD","BK4548","LU1571399168.USD","LU0878866978.SGD","LU1861559042.SGD","LU1894683348.USD","IE00BFXG1179.USD","LU0289961442.SGD","LU1854104046.USD","BDX","LU1150488218.USD","LU1059921491.USD","LU0289739343.SGD","BK4121","BK4082","LU0985320562.USD","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657611338","title":"Morgan Stanley Adjusts PT on Lifestance Health Group to $13 From $10, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657611338","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657611338?lang=en_us&edition=fundamental","pubTime":"2026-08-07 17:29","pubTimestamp":1786094994,"startTime":"0","endTime":"0","summary":"Lifestance Health Group (LFST) has an average rating of buy and mean price target of $12.70, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","LFST","BK4539","FMED","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657775663","title":"10x Genomics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657775663","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657775663?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:01","pubTimestamp":1786050098,"startTime":"0","endTime":"0","summary":"10x Genomics, Inc. reports results for the quarter ended June 30 - Earnings Summary10x Genomics, Inc.TXG.OQreported a quarterly adjusted loss of 14 cents per share for the quarter ended June 30, lower","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TXG","BK4585","BK4588","LU1861558580.USD","BK4548","ARKG","FMED","BK4121","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650213","title":"10x Genomics Q2 Revenue Rises on Atera Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650213","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650213?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:22","pubTimestamp":1786047738,"startTime":"0","endTime":"0","summary":"10x Genomics Q2 revenue rises on Atera demandOverviewUS life science tools firm's Q2 revenue rose 3% yr/yr, beating analyst expectationsCompany posted Q2 net loss as operating expenses rose on lower s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","LU1861558580.USD","CTKB","BK4588","TXG","ARKG","PACB","FMED","BK4548","BK4585","BK4121","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668345","title":"10x Genomics Q2 Swings to Loss, Revenue Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668345","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668345?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:19","pubTimestamp":1786047548,"startTime":"0","endTime":"0","summary":"10x Genomics  reported a Q2 loss late Thursday of $0.14 per diluted share, swinging from earnings of $0.28 a year earlier.Analysts polled by FactSet expected a loss of $0.24.Revenue for the quarter ended June 30 was $151.0 million, down from $172.9 million a year earlier.Analysts expected $146.7 million.For full-year 2026, the company now expects revenue of $610 million to $630 million, up from its prior guidance of $600 million to $625 million. Analysts expect $613.7 million.Shares of 10x Genomics were down nearly 3% in after-hours activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FMED","LU1861559042.SGD","BK4548","ARKG","TXG","BK4585","BK4121","BK4588","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657748","title":"Canada's WELL Health Q2 Revenue Rises, Lifts 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657748","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657748?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:10","pubTimestamp":1786047011,"startTime":"0","endTime":"0","summary":"Canada's WELL Health Q2 revenue rises, lifts 2026 outlookOverviewCanada digital healthcare firm's Q2-2026 revenue rose 12% yr/yr, driven by Canadian Patient ServicesAdjusted EBITDA fell 3% due to prio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4196","LFST","FMED","PRVA","BK4539","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657513","title":"10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657513","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657513?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046746,"startTime":"0","endTime":"0","summary":"10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 150 percent decrease over earnings of $0.28 per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61017245/10x-genomics-q2-eps-0-14-beats-0-24-estimate-sales-151-000m-beat-146-788m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","LU1861558580.USD","ARKG","BK4121","BK4588","TXG","LU1861559042.SGD","BK4585","FMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657065205","title":"10X Genomics Q2 Revenue USD 151 Million Vs. IBES Estimate USD 146.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657065205","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657065205?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:03","pubTimestamp":1786046580,"startTime":"0","endTime":"0","summary":"BRIEF-10X Genomics Q2 Revenue USD 151 Million Vs. IBES Estimate USD 146.8 MillionAug 06 (Reuters) - 10X Genomics Q2 operating income USD -19.6 million.Q2 net income USD -17.9 millionQ2 gross margin 74%outlook FY revenue USD 610-630 million vs. IBES estimate USD 613.9 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXVGJWS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TXG","LU1861559042.SGD","ARKG","BK4585","BK4548","LU1861558580.USD","BK4588","BK4121","FMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657658017","title":"LifeStance Raises Fy2026 Revenue Outlook to $1.685 Billion-$1.725 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2657658017","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657658017?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:07","pubTimestamp":1786028855,"startTime":"0","endTime":"0","summary":"LifeStance raises FY2026 revenue outlook to $1.685 billion-$1.725 billionLifeStance raised full-year 2026 revenue guidance to $1.685-$1.725 billion, a $45 million midpoint increase, implying 20% growt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL23NJdV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","FMED","BK4196","BK4539","LFST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763217","title":"LifeStance Health Group, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763217","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763217?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:31","pubTimestamp":1786023095,"startTime":"0","endTime":"0","summary":"LifeStance Health Group, Inc. reports results for the quarter ended June 30 - Earnings SummaryLifeStance Health Group, Inc.LFST.OQreported quarterly adjusted earnings of 6 cents per share for the quar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431US:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LFST","FMED","BK4196","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680368","title":"Lifestance Health Swings to Q2 Profit as Revenue Rises; Raises 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680368","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680368?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:48","pubTimestamp":1786013305,"startTime":"0","endTime":"0","summary":"Lifestance Health Group  reported Q2 earnings Thursday of $0.06 per diluted share, swinging from a loss of $0.01 a year earlier.Four analysts polled by FactSet expected $0.04.Revenue for the quarter ended June 30 was $435.4 million, up from $345.3 million a year earlier.Analysts surveyed by FactSet expected $414.6 million.The mental health services provider expects Q3 revenue of between $420 million and $440 million. Analysts polled by FactSet expect $418.5 million.For 2026, the company raised its revenue guidance to $1.685 billion to $1.725 billion, from the prior guidance of $1.64 billion to $1.68 billion. Analysts surveyed by FactSet expect $1.66 billion.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4196","FMED","BK4539","LFST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687226","title":"Lifestance Health Lifts Outlook After Strong Q2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687226?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:41","pubTimestamp":1786012882,"startTime":"0","endTime":"0","summary":"Lifestance Health Group ( ($LFST) ) has provided an announcement. LifeStance Health Group reported strong second-quarter 2026 results on August 6, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lifestance-health-lifts-outlook-after-strong-q2-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lifestance-health-lifts-outlook-after-strong-q2-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FMED","BK4535","BK4196","BK4539","LFST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657682535","title":"LifeStance Q2 FY26 Net Income Turns to USD 23.6 Million; Revenue Rises 26% to USD 435.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657682535","media":"Reuters","labels":["shareholding","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657682535?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:13","pubTimestamp":1786011204,"startTime":"0","endTime":"0","summary":"LifeStance Q2 FY26 net income turns to USD 23.6 million; revenue rises 26% to USD 435.4 millionLifeStance posted Q2 2026 revenue of $435.4 million, up 26% from the prior-year quarter.Net income swung ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL2Lkslq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFST","BK4535","BK4196","BK4539","FMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657684161","title":"Lifestance Health Q2 Revenue USD 435.4 Million Vs. IBES Estimate USD 414.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657684161","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657684161?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:01","pubTimestamp":1786010465,"startTime":"0","endTime":"0","summary":"BRIEF-Lifestance Health Q2 Revenue USD 435.4 Million Vs. IBES Estimate USD 414.6 MillionAug 06 (Reuters) - Lifestance Health Q2 adjusted EBITDA USD 66 million vs. IBES estimate USD 54.2 million.Q2 net income USD 23.6 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXJ80WRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4539","BK4196","LFST","FMED"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}